Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine

    ... turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for ...

    Drug last updated 03/24/2016 - 12:32pm.

  2. Since my diagnosis, my mission has been to fight back

    ... was now facing chemotherapy . I began receiving azacitidine (Vidaza®), but my counts were having a hard time recovering. I ... keep me fighting. I recently completed my 34th cycle of azacitidine and have not needed a transfusion in over 2 1/2 years. It has now ...

    Patient Chronicle last updated 04/26/2018 - 10:40am.

  3. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

    ... pursue in AML/MDS. Hypomethylating agents (HMAs) such as azacitidine , while enhancing anti-tumor immune response, concurrently ... molecule upregulation may be an important mechanism of azacitidine resistance. These findings have resulted in multiple clinical ...

    Research Article last updated 04/11/2018 - 9:47am.

  4. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... of this clinical research study is to learn if azacitidine in combination with pembrolizumab can help to control ... Associated Drug(s):  Azacitidine Phase:  ...

    Clinical Trial last updated 05/14/2018 - 1:57pm.

  5. Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

    ... to compare how 2 different drugs, decitabine and azacitidine , when given on a shorter than standard dosing schedule, may ... Associated Drug(s):  Azacitidine Decitabine ...

    Clinical Trial last updated 05/14/2018 - 1:55pm.

  6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce ...

    Research Article last updated 05/22/2017 - 10:52am.

  7. Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

    ... to the current standard treatment, a drug called azacitidine . Although no additional benefit was seen by the new ... by older patients for whom the recently developed drug azacitidine, which can be delivered as an out-patient, represents an important ...

    Research Article last updated 09/29/2017 - 10:32am.

  8. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United ... of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, ...

    Research Article last updated 10/23/2017 - 11:00am.

  9. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

    Journal Title:  Cell Rep Primary Author:  Unnikrishnan A Author(s):  Unnikris...

    Research Article last updated 08/03/2017 - 9:16am.

  10. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

    Journal Title:  Leuk Lymphoma Primary Author:  Press KR Author(s):  Press KR,...

    Research Article last updated 08/03/2017 - 9:15am.